Efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis: A prospective and randomized clinical study
Shi HJ, Song H, Zhao QY, Tao CX, Liu M, Zhu QQ
Medicine · 16 citations
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- University or hospital
- Ningxia University
- University or hospital
- Ningxia Medical University
Based on 2 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2018-09-01 · Medicine (Baltimore) · vol. 97 · issue 37 · p. e12398
- Publisher
- Wolters Kluwer
- Cited
- 23 citations · more than 77% of similar papers · 1.1× the field average
- References
- 56 works
- Access
- Open access (journal) · CC-BY-NC-ND
- Research areas
- Cervical Cancer and HPV Research · Laser Applications in Dentistry and Medicine · Reproductive tract infections research
- Keywords
- Medicine, Cervicitis, Vaginitis, Human papillomavirus, Gynecology, Internal medicine
- MeSH
- humans, papillomaviridae, papillomavirus infections, vaginitis, interferon-alpha, recombinant proteins, antiviral agents, treatment outcome, combined modality therapy, phototherapy, prospective studies, single-blind method, adolescent, adult, middle aged, uterine cervicitis, female, young adult, interferon alpha-2
6 authors
From CN
- Huijuan Shi · correspondingNingxia Medical University; Ningxia Medical University General Hospital
- Hongbin SongChinese PLA General Hospital
- Qianying ZhaoNingxia Medical University; Ningxia Medical University General Hospital
- Chun-Xia TaoNingxia Hui Autonomous Region Peoples Hospital
- Min LiuNingxia Medical University; Ningxia Medical University General Hospital
- Qin-Qin ZhuNingxia Hui Autonomous Region Peoples Hospital
Abstract
Background
We evaluated the efficacy and safety of combined high-dose interferon (IFN) and red light therapy for the treatment of subclinical and latent human papillomavirus (HPV) infections.
Methods
Ninety women diagnosed with subclinical or latent HPV infection were randomized to receive topical application of low-dose recombinant IFNα-2b (1 million IU), high-dose IFNα-2b (9 million IU), or a combination of high-dose IFNα-2b and red light therapy on the cervix and vagina. All patients received treatment once daily for 4 weeks. HPV titer was measured immediately and 4, 8, and 12 weeks after treatment to determine the rates of viral clearance and infection cure. Treatment of HPV-associated vaginitis and cervicitis was also evaluated.
Results
Results showed that immediately and 4, 8, and 12 weeks after treatment, the HPV clearance rates and infection cure rates were higher in the high-dose IFN and combination groups compared to the low-dose IFN group. High-dose IFN and combination therapies were significantly effective against both low-risk and high-risk HPV infections. Although the cure rates for vaginitis and cervicitis were significantly higher in the high- compared to the low-dose IFN group, rates were even higher in the combination group compared to the high-dose IFN group. Mild adverse effects were reported by a very small subset of patients (3/30) in the combination group.
Conclusions
This study suggests that combination of high-dose IFN and red light therapy is safe and effective against subclinical and latent HPV infections.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC-ND).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.